ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gala Therapeutics Receives FDA Approval for RheOx Trial for Chronic Bronchitis
February 25, 2021Gala Therapeutics has announced the U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to commence its pivotal clinical trial called RheSolve, which is designed to evaluate the ... -
Gala Therapeutics Receives FDA Breakthrough Device Designation for RheOx™
September 17, 2019Gala Therapeutics announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FDA) for the RheOx Bronchial Rheoplasty system.
Pharma Sources Insight January 2025
